• Plenary Oral Presentation at SNO will provide latest clinical trial results from the previously enrolled INB-200 studies of autologous gamma-delta T cells for newly diagnosed glioblastoma (GBM)

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming plenary oral presentation at the 29th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), being hosted November 21 - 24, 2024 in Houston, TX. IN8bio will provide longer-term follow-up and additional data demonstrating the activity of its DRI gamma-delta T cell approach in solid tumors from the Phase 1 trial of INB-200. In June 2024, preliminary clinical data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating that 92% of evaluable patients treated in the investigator-initiated trial exceeded the median progression-free survival of 7 months typically observed using standard-of-care therapy with concomitant temozolomide (TMZ).

Details for the SNO oral presentation are as follows:

Title: INB-200: Fully Enrolled Phase 1 Study of Gene-Modified Autologous Gamma-Delta (γδ) T Cells in Newly Diagnosed Glioblastoma Multiforme (GBM) Patients Receiving Maintenance Temozolomide (TMZ)

Presenter: Mina Lobbous, MD, MSPH, Assistant Professor, Cleveland Clinic Lerner College of Medicine

Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

Abstract #: CTIM-09

Session Name: Abstract Session - Clinical Trials

Date and Time: Saturday, November 23, 2024, 11:25 AM - 11:35 AM CST

The abstract will be available online and can be accessed via the conference website at SNO 29th Annual Meeting & Education Day.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on evaluating haplo-matched allogenic gamma-delta T cells given to patients with AML following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. For more information about IN8bio, visit www.IN8bio.com.

Investor & Company Contacts:

Glenn Schulman, PharmD, MPH

203.494.7411

[email protected]

Patrick McCall

IN8bio, Inc.

646.933.5603

[email protected]

Media Contact:

Kimberly Ha

KKH Advisors

917.291.5744

[email protected]